Hyperpigmentation Disorder Treatment Market

A prominent research firm, Cognizance Market Research added a cutting-edge industry report on the “Global Hyperpigmentation Disorder Treatment Market.” The report studies the current as well as past growth trends and opportunities for the market to gain valuable insights during the forecast period from 2022 to 2030.

Global Hyperpigmentation Disorder Treatment Market Analysis

According to cognizance market research, the global hyperpigmentation disorder treatment market was valued at US$ 4,238.4 Million in 2022 and is anticipated to reach US$ 8,171.2 Million by the end of 2030 with a CAGR of 8.6% from 2023 to 2030.

What is the global hyperpigmentation disorder treatment market?

 Hyperpigmentation is a widespread, typically unharmful disorder where some areas of the skin are darker than that of the skin surrounding. It happens when specific skin cells produce an excessive amount of melanin pigment. Freckles, age spots, or significantly darker patches of skin can all be signs of hyperpigmentation. Injuries or inflammation of the skin, UV damage, unnatural skin growths, hormone imbalances, maternity, or other medical disorders can all lead to hyperpigmentation. Hyperpigmentation can also be brought on by various medications, particularly some anticancer medications.

For the treatment of hyperpigmentation, numerous therapies, either alone or in combination with two or more other therapies, have been investigated. The most prevalent conditions are by far melasma and vitiligo. Additional factors that contribute to melasma development include estrogen levels, genetic susceptibility, and phototoxic medication. The majority of the disorders are aesthetically upsetting even if they seem to be harmless. Pigmentation diseases are treated with major treatment types like using, topical medicines, chemical peels, light or laser therapy, cryotherapy, or a combination of these approaches to address the underlying issue. Many histological and immunohistochemical investigations have enriched the picture of the hyperpigmentation disorders therapy market by improving researchers’ understanding of the etiology of melasma. Topical hydroquinone (HQ), topical retinoic acid (RA), topical corticosteroid (triple combination), and topical glycolic acid (GA) (double combination) are a few of the most important therapeutic options.

Throughout the projection period, it is predicted that the market for hyperpigmentation disorder therapy will gain importance due to rising R&D expenditure on cutting-edge technologies and a drop in the stigma attached to pigmentation in society. Additionally, it is projected that increased awareness of skin rejuvenation and possible treatments as well as the rising prevalence of disorders connected to hyperpigmentation would encourage market growth on a global scale.

Global Hyperpigmentation Disorder Treatment Market Outlook

Companies that specialize in the treatment of hyperpigmentation issues have intriguing potential because of cosmeceutical technology breakthroughs and the increased value of using cosmeceuticals in skincare. Large corporations are spending more and more on nanotechnology to develop novel goods, expand their market share, and increase sales.

By increasing the loading capability, solubility, stability, skin permeability, and safety of active ingredients, nanotechnology significantly helps to promote the creation of cosmeceutical formulations. The use of topical hydroquinone, which has less systemic absorption and adequate skin penetration as well as fewer side effects, is an appealing method for treating hyperpigmentation.

The need for post-inflammatory hyperpigmentation (PIH) therapies caused by the prevalence of persons with darker skin tones is boosting the marketplace for the treatment of hyperpigmentation illnesses.

Despite an extensive body of research on the pathophysiology of PIH, there is still a necessity in the world market for the treatment of hyperpigmentation disorders. Several compounds, including dexamethasone, tretinoin, and hydroquinone, are being researched to close this gap.

Because of the COVID-19 pandemic, the market for treating pigmentation disorders has indeed been impacted. 1,360 dermatologists in the UK were found to be assessing the consequences of the epidemic, according to a report by Hamilton Fraser Cosmetic Insurance. The poll found that 99.78% of respondents and their professions were affected by the epidemic.

With the rise in launches and R&D activities by top corporations, the industry is expanding. For instance, Incyte Corporation was conducting a phase II US clinical trial for the medication Ruxolitinib to treat vitiligo, as reported by the National Clinical Trials (NCT) Registry. The market will grow if the drug Ruxolitinib is soon approved for the treatment of Vitiligo.

Segment Analysis:

The study offers a thorough review of the worldwide market for treating hyperpigmentation disorders by therapy type (topical treatment), end-user, illness indication, and geography.

Based on the type of treatment, there are two types of treatment available there, pharmacological therapy & non -pharmacological therapy.  The pharmacological segment is further divided into synthetic origin & natural origin. The synthetic segment consists of hydroquinone azelaic acid, vitamin C, & topical corticosteroids. Whereas the natural segment consists of Kojik acid, citrus extracts & licorice extract. A considerable percentage of the market is expected to be occupied by topical drugs.

 The non -non-pharmacological segment consists of laser treatments, chemical peels, phototherapy, and microdermabrasion. Patients with hyperpigmentation problems see dermatologists more often, and topical medications are frequently given to these patients. As a result of better clinical results for individuals with pigmentation problems, the topical therapy category presently holds a monopoly on the global market. The most common topical medications worldwide are hydroquinone, L-ascorbic acid, azelaic acid, etc.

Based on end users, the hyperpigmentation disorders treatment statistics comprise hospitals, aesthetic clinics, dermatological centers, and others. The hospital sector accounted for most of the market revenue for the treatment of hyperpigmentation disorders in 2022, and it is anticipated to increase at the fastest rate from 2022 to 2030. A surge in dermatological and aesthetic clinics is what is driving this market. The other group, however, is also anticipated to grow during the prediction period. Producers and distributors of cosmeceuticals for hyperpigmentation are improving their supply chains to satisfy the increasing need for treatments for hyperpigmentation diseases.

Melasma, post-inflammatory hyperpigmentation & solar lentigines are part of the Hyperpigmentation Disorders Therapy Market segmentation based on disease indication. In 2022, the market for treating hyperpigmentation disorders was dominated by the melasma category, and during the forecast period of 2022–2030, it is anticipated to develop at the fastest rate. Because of its high occurrence in white people, who make up between 55% and 60% of the world’s population, melasma presently leads the ailment category. 90% of women worldwide experience melasma, which is accompanied by hormonal changes, pregnancy, and the use of reproductive control.

Geographical Analysis

Based on geography the market for global hyperpigmentation disorders treatment has been categorized into North America, Europe, Asia Pacific, Latin America, and Middle East and Africa. North America, Europe, and the Asia-Pacific region were the most preferred regions for hyperpigmentation problem treatment. Asia Pacific will continue to dominate the worldwide market for treatments for hyperpigmentation disorders over the projected period because of factors such as rising self-consciousness about one’s appearance, increased usage of minimally invasive procedures, and a highly developed healthcare system.

As reported in a 2022 article from the National Centre for Biotechnology Information, US National Library of Medicine, albinism is more common in the American region, with rates of 1:10,000 among African Americans and 1:36,000 overall. Therefore, it is projected that as albinism grows more common in the country, the market for treating hyperpigmentation problems will expand.

Yet the region with the highest CAGR is Asia Pacific, where growth is being led by China, India, and Japan. Due to reasons such as the increasing interest of key players in developing Asian countries, penetration, and adoption of cutting-edge technology, rising disposable incomes, and expanding government assistance, the market for treatments for hyperpigmentation disorders is growing in this region.

An increase in the use of laser therapy for a variety of skin issues, as well as a decline in societal stigmas and an increase in the adoption of treatment options for pigmentation disorders, are projected to propel the regional market.